Disease · MONDO_0005789
hepatitis D virus infection
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hepatitis D virus infection. Diseases, record MONDO_0005789. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005789
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
- HDV, Hepatitis D, Hepatitis D virus, Hepatitis delta virus caused hepatitis, Hepatitis delta virus hepatitis, hepatitis delta, hepatitis type D
- Open Targets
Drugs21
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BULEVIRTIDE | CHEMBL4297711 | Protein | Approval | TTD | 9 | 8 | 8 | Drugs and targets |
| PEGINTERFERON ALFA-2A | CHEMBL1201560 | Protein | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| LONAFARNIB | CHEMBL298734 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 4 | 4 | Drugs and targets |
| HEPALATIDE | CHEMBL4650398 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| INTERFERON ALFA-2A | CHEMBL2108508 | Protein | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| RITONAVIR | CHEMBL163 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TOBEVIBART | CHEMBL5314621 | Antibody | Phase 3 | ClinicalTrials.gov | 3 | 2 | 2 | Drugs and targets |
| ELEBSIRAN | CHEMBL5315044 | Oligonucleotide | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| PEGINTERFERON ALFA-2B | CHEMBL1201561 | Protein | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TENOFOVIR ANHYDROUS | CHEMBL483 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 21
See all 21 drugsTargets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| IFNAR1 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator | Phase 3 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 4 | Interferon alpha/beta receptor agonist; Interferon alpha/beta receptor positive modulator | Phase 3 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| SLC10A1 | Hepatic sodium/bile acid cotransporter | 2 | Bile acid transporter inhibitor | Approval | https://conductscience.org/library/genes/6554 | Drugs and targets |
| CYP3A4 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/1576 | Drugs and targets |
| CYP3A43 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/64816 | Drugs and targets |
| CYP3A5 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/1577 | Drugs and targets |
| CYP3A7 | Cytochrome P450 3A | 1 | Cytochrome P450 3A inhibitor | Phase 3 | https://conductscience.org/library/genes/1551 | Drugs and targets |
| FNTA | Protein farnesyltransferase | 1 | Protein farnesyltransferase inhibitor | Phase 3 | https://conductscience.org/library/genes/2339 | Drugs and targets |
| FNTB | Protein farnesyltransferase | 1 | Protein farnesyltransferase inhibitor | Phase 3 | https://conductscience.org/library/genes/2342 | Drugs and targets |
| IFNLR1 | Interferon lambda receptor | 1 | Interferon lambda receptor agonist | Phase 2 | https://conductscience.org/library/genes/163702 | Drugs and targets |
1 to 10 of 14
See all 14 targetsTrials31
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03852433 | Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD) | Phase 2 | 175 | 2024-07-29 | Chronic Hepatitis Delta | BULEVIRTIDE, INTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT03852719 | Study to Assess Efficacy and Safety of Bulevirtide in Participants With Chronic Hepatitis Delta (CHD) | Phase 3 | 150 | 2022-10-28 | Chronic Hepatitis Delta | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT03546621 | A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D | Phase 2 | 120 | 2019-12-30 | Chronic Hepatitis D Infection With Hepatitis B | BULEVIRTIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02577029 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) | Phase 2 | 79 | 2019-04-12 | Hepatitis B, Hepatitis D | ENTECAVIR, PEGINTERFERON ALFA-2A, TENOFOVIR DISOPROXIL | Its record names the disease | ClinicalTrials.gov |
| NCT00686790 | Efficacy of Peginterferon Alfa-2b in Previously Untreated Subjects With Chronic Hepatitis B and D Co-infection (Study P04603) | Phase 3 | 68 | 2011-01-17 | Hepatitis D, Chronic, Hepatitis B, Chronic | PEGINTERFERON ALFA-2B | Its record names the disease | ClinicalTrials.gov |
| NCT04535544 | A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus | Phase 2 | 52 | 2024-11-06 | Hepatitis D, Chronic | ENTECAVIR, TENOFOVIR ALAFENAMIDE, TENOFOVIR DISOPROXIL | Its record names the disease | ClinicalTrials.gov |
| NCT02765802 | A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection | Phase 2 | 33 | 2023-01-17 | Hepatitis D, Chronic | PEGINTERFERON LAMBDA-1A | Its record names the disease | ClinicalTrials.gov |
| NCT02732639 | A Study of Pegylated Interferon (PEG-IFN) Alfa-2a (Pegasys) in Participants With Chronic Hepatitis D (CHD) | Phase 3 | 31 | 2016-08-26 | Hepatitis D, Chronic | INTERFERON ALFA-2A | Its record names the disease | ClinicalTrials.gov |
| NCT02511431 | Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir | Phase 2 | 22 | 2018-05-24 | Hepatitis D | LONAFARNIB, RITONAVIR | Its record names the disease | ClinicalTrials.gov |
| NCT01495585 | Lonafarnib for Chronic Hepatitis D | Phase 2 | 14 | 2016-08-31 | Hepatitis D | LONAFARNIB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 31
See all 31 trialsComparisons in its trials10
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Peginterferon Lambda-1A 180 μg vs Peginterferon Lambda-1A 120 μg: Number of Patients With a Durable Virologic Response | 5 of 14 | 3 of 19 | 33 | NCT02765802 | Trial comparisons |
| Lambda 180 μg vs Lambda 120 μg: deaths from any cause | 0 of 14 | 0 of 19 | 33 | NCT02765802 | Trial comparisons |
| Lambda 180 μg vs Lambda 120 μg: serious adverse events | 2 of 14 | 5 of 19 | 33 | NCT02765802 | Trial comparisons |
Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With Alanine Aminotransferase (ALT) Normalization Plus Negative Hepatitis D Virus (HDV) Ribonucleic Acid (RNA) at 48 Weeks After End of Treatment | 0 of 6 | 1 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With ALT Normalization Plus Negative HDV RNA at End of Treatment | 0 of 6 | 0 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With Negative HDV RNA at 48 Weeks After End of Treatment | 0 of 6 | 1 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With ALT Normalization at End of Treatment | 1 of 6 | 0 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With ALT Normalization at 48 Weeks After End of Treatment | 3 of 6 | 1 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: Number of Participants With Negative HDV RNA at End of Treatment | 1 of 6 | 2 of 6 | 12 | NCT02731131 | Trial comparisons |
| Group A: Monotherapy With Peginterferon Alfa-2a vs Group B: Combination With Peginterferon Alfa-2a + Ribavirin: serious adverse events | 0 of 6 | 0 of 6 | 12 | NCT02731131 | Trial comparisons |
Papers from its trials26
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005789
GET https://conductscience.org/api/diseases/v1/MONDO_0005789/drugs?page=2